Mea nānā mele - t

ʻO ka noʻonoʻo hoʻomohalaʻana o nā kaʻa - t cell therapy

Hiki ke hoʻohanaʻia ka hoʻomohalaʻana o ke kaʻa - T Cell Therapy e hoʻihoʻi hou i ka makahiki 1989, i ka wā e hōʻike muaʻia ai nāʻepekema G a meʻekolu mauʻepekema A laila, i ka makahiki 2008,ʻo ka Cred Hutchion Cancer Institute i hoʻohana mua i ka Card TR CORLL e mālama i ka palekana o kēiaʻano hana. Ma ka 2010,ʻo ka hihia kūleʻa mua o CDER19 - Ka hōʻikeʻana i nā kaʻa - T Trapy no B - keleponaʻo LordPhoma ma United States. A laila ma ka makahiki 2011 Ma ka 2017,ʻo ka meaʻai a me ka US a me ka lāʻau lapaʻau a me ka lāʻau lapaʻau (FDA) iʻae i kaʻaeʻana i ke Kaina Kūʻai Kūʻai Nui I ka makahiki hoʻokahi, YeCarta, ka lua o nā kaʻa kaʻa. I 2020, ua aponoia ka FDA i ke kolu o ka Carr Car T - Celb i ka huahana Terapy Protect Tercartus. I 2021, ua kauohaʻia ka FDA iʻelua kaʻa o Breit, BrayanZip a Hebecma, no ka mālamaʻana i ka melemele nui a he lehulehu hoʻi i ka moholima. I ka makahiki hoʻokahi

I 2022, ua aponoia ka FDA i ka mana o ke kālepaʻana o Carvykti, kahi kaʻa - B ccma) no ka hoʻomahaʻana i ka minelma.

I kēia manawa, ua hoʻokomoʻo Car T Cell Therapy i komo i ka ERA o ka Era o ka Cancer Immunotherapy a wehe i kahi nani nani i ka honua.

He aha ke kaʻa - t cell therapy

ʻO ke kaʻa kaʻa Tely Therapy,ʻikeʻiaʻo iaʻo Chimeric Antigen Antigor T Mobile Telmuniteray ʻAe kēia iā lākou eʻike kūikawā i nā'āpana tumor a me ka hoʻopiliʻana i kēlā mau mea i ka maʻi e mālama i ka maʻi.

Iit papa Papa helu Papa kiʻekiʻe Papa kūʻai

Kaʻa - T